Neural nAChRs PET imaging probes

Nuclear Medicine Communications

Volumn 35, Issue 2, 2014, Pages 135-143

  Mo, Ye Xiong ^a   Yin, Ya Fu ^a   Li, Ya Ming ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

brain; nicotinic acetylcholine receptors; PET; radioligands

Indexed keywords

3 (2 AZETIDINYLMETHOXY)PYRIDINE; BUNGAROTOXIN RECEPTOR; NICOTINE C 11; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOLIGAND; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

AUTISM; DRUG TARGETING; HUMAN; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

DISEASE; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, NICOTINIC;

EID: 84891558603     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000032     Document Type: Review

References (87)

1. Court JA, Martin-Ruiz C, Graham A, Perry E. Nicotinic receptors in human brain: topography and pathology. J Chem Neuroanat 2000; 20:281-298.
2. Levin ED. Nicotinic receptor subtypes and cognitive function. J Neurobiol 2002; 53:633-640.
3. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Vincent P, et al. Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 1995; 374:65-67.
4. Zoli M, Picciotto MR, Ferrari R, Cocchi D, Changeux JP. Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors. EMBO J 1999; 18:1235-1244.
5. Granon S, Faure P, Changeux JP. Executive and social behaviors under nicotinic receptor regulation. Proc Natl Acad Sci USA 2003; 100:9596-9601.
6. Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, et al. Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 1997; 17:9165-9171.
7. Young JW, Finlayson K, Spratt C, Marston HM, Crawford N, Kelly JS, et al. Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology 2004; 29:891-900.
8. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002; 125:1483-1495.
9. Martin-Ruiz CM, Lee M, Perry RH, Baumann M, Court JA, Perry EK. Molecular analysis of nicotinic receptor expression in autism. Mol Brain Res 2004; 123:81-90.
10. Court J, Spurden D, Lloyd S, McKeith I, Ballard C, Cairns N, et al. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: a-bungarotoxin and nicotine binding in the thalamus. J Neurochem 1999; 73:1590-1597.
11. Guan ZZ, Zhang X, Blennow K, Nordberg A. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 1999; 10:1779-1782.
12. Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, Gillen KM, et al. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000; 23:351-364.
13. 2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett 2000; 287:109-112.
14. Warpman U, Nordberg A. Epibatidine and ABT 418 reveal selective losses of alpha 4 beta 2 nicotinic receptors in Alzheimer brains. Neuroreport 1995; 6:2419-2423.
15. Martin-Ruiz CM, Piggott M, Gotti C, Lindstrom J, Mendelow AD, Siddique MS, et al. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology 2000; 39:2830-2839
16. Rezvani AH, Cauley MC, Johnson EC, Gatto GJ, Levin ED. Effects of AZD3480, a neuronal nicotinic acetylcholine receptor agonist, and donepezil on dizocilpine-induced attentional impairment in rats. Psychopharmacology (Berl) 2012; 223:251-258.
17. Dunbar GC, Inglis F, Kuchibhatla R, Sharma T, Tomlinson M, Wamsley J. Effect of ispronicline, a neuronal nicotinic acetylcholine receptor partial agonist, in subjects with age associated memory impairment (AAMI). J Psychopharmacol 2007; 21:171-181.
18. Locke SM, Newhouse PA, Mazzulla E, Wilkins H, Potter AS. Novel nicotinic agonist AZD3480 improves cognition in a randomized control trial of adults with attention-deficit/hyperactivity disorder. Presented at the Society for Neuroscience Annual Meeting, 2010; San Diego, CA, 563; p. 17.
19. Rollema H, Hajos M, Seymour PA, Kozak R, Majchrzak MJ, Guanowsky V, et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem Pharmacol 2009; 78:813-824.
20. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474-3477.
21. Coe JW, Vetelino MG, Bashore CG, Wirtz MC, Brooks PR, Arnold EP, et al. In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 2005; 15:2974-2979.
22. 2 nicotinic acetylcholine receptor ligand: effects on dizocilpine and scopolamine-induced attentional impairments in female Sprague-Dawley rats. Psychopharmacology (Berl) 2011; 215:621-630.
23. Schneider JS, Tinker JP, Van Velson M, Menzaghi F, Lloyd GK. Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low dose MPTP-treated monkeys. J Pharmacol Exp Ther 1999; 290:731-739.
24. Briggs CA, Anderson DJ, Brioni JD, Buccafusco JJ, Buckley MJ, Campbell JE, et al. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 1997; 57:231-241.
25. Buccafusco JJ, Terry AV Jr, Decker MW, Gopalakrishnan M. Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys. Biochem Pharmacol 2007; 74:1202-1211.
26. 7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 2007; 321:716-725.
27. 7 receptors. Psychopharmacology (Berl) 2004; 172:375-383.
28. Langer O, Müller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 2004; 5:463-481.
29. Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radio-ligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 2010; 86:575-584.
30. 11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET. Int J Rad Appl Instrum B 1992; 19:871-880.
31. 11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl) 1994; 115:31-36.
32. Marutle A, Warpman U, Bogdanovic N, Lannfelt L, Nordberg A. Neuronal nicotinic receptor deficits in Alzheimer patients with the Swedish amyloid precursor protein 670/671 mutation. J Neurochem 1999; 72:1161-1169.
33. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc Brain Metab Rev 1992; 4:303-328.
34. Nordberg A. Human nicotinic receptors-their role in aging and dementia. Neurochem Int 1994; 25:93-97.
35. 11C-nicotine in brain of Alzheimer patients as visualized by positron emission tomography. J Neural Transm Park Dis Dement Sect 1990; 2:215-224.
36. 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) 2006; 188:509-520.
37. 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. Psychopharmacology (Berl) 2007; 191:1005-1014.
38. Rose JE, Mukhin AG, Lokitz SJ, Turkington TG, Herskovic J, Behm FM, et al. Kinetics of brain nicotine accumulation in dependent and nondependent smokers assessed with PET and cigarettes containing 11C-nicotine. Proc Natl Acad Sci USA 2010; 107:5190-5195.
39. 11C]nicotine in human brain. Psychopharmacology (Berl) 2010; 209:383-394.
40. 3H]-nicotine in the mouse brain. Life Sci 1989; 44:1123-1132.
41. Abreo MA, Lin NH, Garvey DS, Gunn DE, Hettinger AM, Wasicak JT, et al. Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. J Med Chem 1996; 39:817-825.
42. 2 nicotinic acethylcholine receptor ligand. Neuropharmacology 1996; 35:725-734.
43. Koren AO, Horti AG, Mukhin AG, Gündisch D, Kimes AS, Dannals RF, et al. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem 1998; 41:3690-3698.
44. 2 nicotinic acetylcholine receptors. NeuroReport 1999; 10:2715-2721.
45. Molina PE, Ding YS, Carroll FI, Liang F, Volkow ND, Pappas N, et al. Fluoro-norchloroepibatidine: preclinical assessment of acute toxicity. Nucl Med Biol 1997; 24:743-747.
46. 18F]fluoro-A-85380. J NucI Med 1999; 40:1374-1380.
47. 18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J 2003; 17:1331-1333.
48. 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med 2003; 44:596-601.
49. 18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine as a PET tracer for nicotinic acetylcholine receptors. Nucl Med Biol 2000; 27:381-389.
50. 18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor. Nucl Med Biol 2000; 27:51-56.
51. 18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse 2004; 53:184-189.
52. Ellis JR, Nathan PJ, Villemagne VL, Mulligan RS, Ellis KA, Tochon-Danguy HJ, et al. The relationship between nicotinic receptors and cognitive functioning in healthy aging: an in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380. Synapse 2009; 63:752-763.
53. 3H]nicotine binding sites in human brain. J Neurochem 1988; 50:1243-1247.
54. 18F-FA-85380. J Nucl Med 2008; 49:1628-1635.
55. Brody AL, Mandelkern MA, London ED, Olmstead RE, Farahi J, Scheibal D, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006; 63:907-915.
56. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)I]-A-85380. Neuropsychopharmacology 2004; 29:108-116.
57. 18F]F-A85380 in Parkinson's disease. Nucl Med Biol 2006; 33:305-309.
58. 18F]fluoro-A-85380 PET study. Neurobiol Learn Mem 2008; 90:404-412.
59. 18F]fluoro-A-85380 PET. Psychopharmacology (Berl) 2009; 202:79-91.
60. Kendziorra K, Wolf H, Meyer PM, Barthel H, Hesse S, Becker GA, et al. Decreased cerebral a4b2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. Eur J Nucl Med Mol Imaging 2011; 38:515-525.
61. 2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 2009; 66:866-877.
62. Kas A, Bottlaender M, Gallezot GD, Vidailhet M, Villafane G, Gregoire MC, et al. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 2009; 29:1601-1608.
63. 18F]F-A- 85380. Neuroimage 2007; 34:1352-1362.
64. 18F]fluoro-A-85380, a novel radioligand for in vivo imaging of central nicotinic acetylcholine receptors. Life Sci 2000; 67:463-469.
65. Horti AG, Wong DF. Clinical perspective and recent development of PET radioligands for imaging cerebral nicotinic acetylcholine receptors. PET Clin 2009; 4:89-100.
66. 18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol 2006; 33:295-304.
67. 125I-a-bungaratoxin binding sites in the brain of Macca mulatta. J Comp Neurol 2003; 461:49-60.
68. 18F-nifene binding to a4b2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Res 2011; 1:6.
69. Hillmer AT, Wooten DW, Moirano JM, Slesarev M, Barnhart TE, Engle JW, et al. Specific a4b2 nicotinic acetylcholine receptor binding of [F-18]nifene in the rhesus monkey. Synapse 2011; 65:1309-1318.
70. 18F-nifene kinetics in the nonhuman primate. J Nucl Med 2012; 53:1471-1480.
71. 18F]Nifene biodistribution and dosimetry based on whole-body PET imaging of mice. Nucl Med Biol 2013; 40:289-294.
72. 18F-fluoropropyl)-3-(2-(S)-pyrrolidinylmethoxy)-pyridine, in rodents and PET in nonhuman primate. J Nucl Med 2005; 46:130-140.
73. 18F-ZW-104: a new radioligand for imaging neuronal nicotinic acetylcholine receptors-in vitro binding properties and PET studies in baboons. J Nucl Med 2009; 50:1349-1355.
74. 18F]ZW-104, a new radioligand for imaging alpha2-alpha3-alpha4/beta2 central nicotinic acetylcholine receptors: evaluation in mutant mice. Synapse 2010; 64:570-572.
75. Horti AG, Villemagne VL. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des 2006; 12:3877-3900.
76. 18F-AZAN, a radioligand with improved brain kinetics. J Nucl Med 2012; 53:121-129.
77. 18F]fluoropyridin-2-yl)-5- pyridinyl]-7-azabicyclo [2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinicacetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. J Med Chem 2008; 51:4751-4764.
78. 18F-AZAN, a radioligand with optimal brain kinetics. J Nucl Med 2013; 54:1308-1314.
79. Mullen G, Napier J, Balestra M, DeCory T, Hale G, Macor J, et al. (-)-Spiro [1-azabicyclo[2.2.2]octane-3, 5-oxazolidin-2-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor. J Med Chem 2000; 43:4045-4050.
80. Pomper MG, Phillips E, Fan H, McCarthy DJ, Keith RA, Gordon JC, et al. Synthesis and biodistribution of radiolabeled alpha 7 nicotinic acetylcholine receptor ligands. J Nucl Med 2005; 46:326-334.
81. Ogawa M, Nishiyama S, Tsukada H, Hatano K, Fuchigami T, Yamaguchi H, et al. Synthesis and evaluation of new imaging agent for central nicotinic acetylcholine receptor a7 subtype. Nucl Med Biol 2010; 37:347-355.
82. 125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 1995; 47:164-171.
83. Toyohara J, Wu J, Hashimoto K. Recent development of radioligands for imaging a7 nicotinic acetylcholine receptors in the brain. Curr Top Med Chem 2010; 10:1544-1557.
84. Peters D, Olsen GM, Nielsen EO, Timmermann DB, Loechel SC, Mikkelsen JD, et al. Novel 1, 4-diazabicyclo[3.2.2]nonyl oxadiazolyl derivatives and their medical use. 2007; WO/2007/138037. International Application No.: PCT/EP2007/055168. Available at: http://www.wipo.int/pct/en/.
85. 11C-NS14492 as a novel PET ligand for imaging cerebral alpha7 nicotinic receptors: in vivo evaluation and drug occupancy measurements. J Nucl Med 2011; 52:1449-1456.
86. 18F]NS10743. Eur J Nucl Med Mol Imaging 2011; 38:1541-1549.
87. 18F]NS14490 for molecular imaging of a7 nicotinic acetylcholine receptors. Bioorg Med Chem 2013; 21:2635-2642.